Abstract: A long-acting brexpiprazole preparation for injection and a preparation method therefor. The preparation method therefor comprises: (a) dissolving brexpiprazole in an organic solvent to form a brexpiprazole solution; (b1) pumping the brexpiprazole solution into a sheared or violently stirred precipitation solvent, so as to precipitate brexpiprazole, or (b2) pumping the precipitation solvent into the sheared or violently stirred brexpiprazole solution, so as to precipitate brexpiprazole; (c) filtering and optionally using water to wash an obtained solid; and (d1) drying the obtained solid, and respectively packaging the dried solid and an auxiliary material solution to obtain the long-acting brexpiprazole preparation for injection, or (d2) dispersing the obtained solid into the auxiliary material solution to obtain the long-acting brexpiprazole preparation for injection.

Abstract: The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also relates to a preparation method for the solid and the pharmaceutical composition thereof, and an application thereof in the treatment of mental diseases. According to the present disclosure, the lurasidone solid prepared has controllable particle size and has Dv5O particle size of 6 ?m to 110 ?m. The good particle size stability can also he maintained in the pharmaceutical composition. The lurasidone suspension preparation obtained by the method is fast-acting, has a long sustained release period, and can effectively reduce the risk caused by poor patient compliance.

Abstract: Antibodies selectively directed against SUM04 polypeptides are provided. The antibodies are useful research tools and further in the diagnosis and treatment of Type 1 diabetes.

Abstract: Novel nucleic acids associated with Type 1 diabetes. Also provided are polypeptides encoded by the nucleic acids associated with T1D. The invention also provides methods for facilitating the diagnosis or pre-diagnosis of T1D through the use of such nucleic acids and polypeptides. This invention further provides compositions for the treatment of Type 1 diabetes.

Abstract: Novel nucleic acids associated with Type 1 diabetes. Also provided are polypeptides encoded by the nucleic acids associated with T1D. The invention also provides methods for facilitating the diagnosis or pre-diagnosis of T1D through the use of such nucleic acids and polypeptides. This invention further provides compositions for the treatment of Type 1 diabetes.

Abstract: A new gene family involved in cell cycle regulation was discovered. This family has been termed activators of cyclin-dependent kinases (ACDKs). A number of ACDK genes have been cloned and sequenced. Proteins encoded by ACDK genes specifically were shown to interact with CDKs and pRb, and to upregulate the kinase activity of a CDK using pRb as a substrate. Progression of a cell through the cell cycle can be regulated by modulating ACDK expression in the cell.

Abstract: A new gene family involved in cell cycle regulation was discovered. This family has been termed activators of cyclin-dependent kinases (ACDKs). A number of ACDK genes have been cloned and sequenced. Proteins encoded by ACDK genes specifically were shown to interact with CDKs and pRb, and to upregulate the kinase activity of a CDK using pRb as a substrate. Progression of a cell through the cell cycle can be regulated by modulating ACDK expression in the cell.

Abstract: Novel nucleic acids associated with Type 1 diabetes. Also provided are polypeptides encoded by the nucleic acids associated with T1D. The invention also provides methods for facilitating the diagnosis or pre-diagnosis of T1D through the use of such nucleic acids and polypeptides. This invention further provides compositions for the treatment of Type 1 diabetes.